# MSCAN: ctDNA Methylation as Prognostic and Theranostic Tool for Pancreatic Cancer

> **NCT07045571** · — · RECRUITING · sponsor: **Yingbin Liu, MD, PhD, FACS** · enrollment: 1000 (estimated)

## Conditions studied

- Pancreatic Neoplasm
- Pancreas Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07045571
- **Lead sponsor:** Yingbin Liu, MD, PhD, FACS
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2022-10-30
- **Primary completion:** 2026-01-22
- **Final completion:** 2026-07-22
- **Target enrollment:** 1000 (ESTIMATED)
- **Last updated:** 2025-07-01

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07045571

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07045571, "MSCAN: ctDNA Methylation as Prognostic and Theranostic Tool for Pancreatic Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07045571. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*